Regen BioPharma Inc
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from au… Read more
Regen BioPharma Inc (RGBP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.030x
Based on the latest financial reports, Regen BioPharma Inc (RGBP) has a cash flow conversion efficiency ratio of 0.030x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-197.94K) by net assets ($-6.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Regen BioPharma Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Regen BioPharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Regen BioPharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Regen BioPharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PFA Invest Kreditobligationer Fund
CO:PFIKRB
|
N/A |
|
DNI BETEILIGUNGEN
MU:DN1
|
N/A |
|
Nuwara Eliya Hotels Co PLC
CM:NEHN0000
|
N/A |
|
WINSTAR CAPITAL BERHAD
KLSE:0336
|
N/A |
|
Pemtron Corp.
KO:168360
|
N/A |
|
M'BISHI UFJ FINL - Dusseldorf Stock Exchang
DU:MFZ
|
N/A |
|
Sanyo Special Steel Co., Ltd.
PINK:SYPLF
|
0.038x |
|
Easy Technologies Inc
PINK:EMYSF
|
0.058x |
Annual Cash Flow Conversion Efficiency for Regen BioPharma Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Regen BioPharma Inc from 2014 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $-6.28 Million | $-383.59K | 0.061x | -54.24% |
| 2024-09-30 | $-5.19 Million | $-693.14K | 0.133x | +291.64% |
| 2023-09-30 | $-5.10 Million | $-173.92K | 0.034x | -54.88% |
| 2022-09-30 | $-8.04 Million | $-606.92K | 0.076x | -9.94% |
| 2021-09-30 | $-13.49 Million | $-1.13 Million | 0.084x | +3399.11% |
| 2020-09-30 | $-7.33 Million | $18.64K | -0.003x | -105.76% |
| 2019-09-30 | $-10.91 Million | $-481.79K | 0.044x | -74.47% |
| 2018-09-30 | $-9.12 Million | $-1.58 Million | 0.173x | -52.04% |
| 2017-09-30 | $-5.25 Million | $-1.89 Million | 0.361x | -87.34% |
| 2016-09-30 | $-586.90K | $-1.67 Million | 2.849x | -97.49% |
| 2015-09-30 | $-97.19K | $-11.01 Million | 113.310x | +1866.62% |
| 2014-09-30 | $-129.63K | $-746.89K | 5.762x | -- |